Loading...
XNAS
RDHL
Market cap7kUSD
Apr 03, Last price  
2.26USD
1D
-7.76%
1Q
-65.34%
Jan 2017
-99.98%
IPO
-99.98%
Name

Redhill Biopharma Ltd

Chart & Performance

D1W1MN
P/E
0.00
P/S
0.00
EPS
7,365.57
Div Yield, %
—
Shrs. gr., 5y
62.55%
Rev. gr., 5y
-4.87%
Revenues
7m
-89.46%
023,00016,00012,0007,014,0003,000101,0004,007,0008,360,0006,291,00064,359,00085,757,00061,800,0006,513,173
Net income
24m
P
-2,544,000-15,503,000-10,326,000-10,628,000-10,711,000-21,090,000-29,370,000-45,544,000-38,820,000-43,634,000-89,017,000-114,311,000-59,245,00023,916,000
CFO
-36m
L+22.73%
-1,632,000-4,691,000-6,795,000-8,436,000-12,229,000-17,826,000-28,258,000-44,769,000-34,462,000-40,749,000-48,579,000-65,047,000-29,185,000-35,820,000

Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
URL
https://www.redhillbio.com/
IPO date
Feb 01, 2011
Employees
113
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
6,513
-89.46%
61,800
-27.94%
Cost of revenue
37,953
104,644
Unusual Expense (Income)
NOPBT
(31,440)
(42,844)
NOPBT Margin
Operating Taxes
(12,424)
Tax Rate
NOPAT
(31,440)
(30,420)
Net income
23,916
-140.37%
(59,245)
-48.17%
Dividends
Dividend yield
Proceeds from repurchase of equity
13,959
23,806
BB yield
-5.90%
-10.96%
Debt
Debt current
718
116,248
Long-term debt
1,628
13,918
Deferred revenue
Other long-term liabilities
1,281
3,373
Net debt
(4,160)
110,033
Cash flow
Cash from operating activities
(35,820)
(29,185)
CAPEX
(11)
(198)
Cash from investing activities
4
8,302
Cash from financing activities
21,439
11,453
FCF
(23,037)
(33,391)
Balance
Cash
6,359
19,983
Long term investments
147
150
Excess cash
6,180
17,043
Stockholders' equity
(386,296)
(431,025)
Invested Capital
390,819
508,689
ROIC
ROCE
EV
Common stock shares outstanding
6,478
1,548
Price
36.50
-73.98%
140.30
-94.56%
Market cap
236,449
8.85%
217,219
-92.76%
EV
232,289
327,252
EBITDA
(29,450)
(34,690)
EV/EBITDA
Interest
367
41,333
Interest/NOPBT